Tacrolimus dose study in early kidney transplant patients
Part of Immune system & allergy, Infections, Kidney & urinary clinical trials.
This study looks at how tacrolimus (a rejection-preventing medicine) should be dosed in the first days to years after a kidney transplant. It may help personalize dosing by comparing different patient groups, including using genetic testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a kidney transplant very recently (no more than 7 days ago).
- Your transplant team started you on tacrolimus, along with mycophenolate/mycophenolic acid or everolimus.
- You are expected to stay on tacrolimus for at least the first 4 years (no planned early switch to a different rejection medicine like belatacept).
- You can take part in genetic testing and will sign consent for it.
- If you can become pregnant, you must use effective birth control and agree to it during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking immunosuppressive drugs (tacrolimus and mycophenolate mofetil) just once a day, instead of twice, works as well for people who recently had a liver transplant. The goal is to make the medication schedule easier and possibly safer.
This study looks at how well tacrolimus, a medicine that prevents kidney rejection, works in people after a kidney transplant. By checking your immune system and your medicine levels, the goal is to find the best dose for each person to keep your new kidney healthy.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
This study tests whether doing a simple genetic test before starting the anti-rejection drug tacrolimus can lead to better dosing and outcomes in kidney transplant patients. It also looks at whether this approach is cost-effective.
This study tests a personalized approach to dosing tacrolimus (an anti-rejection medicine) in children who have had a kidney transplant. By using each child's own data, doctors hope to find the best dose to keep the transplanted kidney healthy and avoid side effects.
This study tests whether giving tacrolimus at a time of day matched to each patient's body clock can improve safety and effectiveness after a kidney transplant. It may help recipients maintain stable drug levels with fewer side effects.
Hear when a new Kidney Transplant Failure and Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.